42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement38th Annual Miami Breast Cancer Conference® - Abstracts
Volume 35
Issue suppl 1
Pages: 22

Reshma Shinde, MBBS, MPH1; Eric Sarpong, PhD1; Puneet Singhal, PhD, PharmB, MS1

1Merck & Co, Inc, Kenilworth, NJ, USA

Background

Olaparib (Lynparza) is a PARP inhibitor approved for treatment in patients with germline BRCA (gBRCA)–mutated, HER2-negative metastatic breast cancer (mBC), since January 2018 in the US. Currently, real-world evidence for demographic, clinical, and treatment characteristics of patients with mBC receiving olaparib is limited.

Materials and methods

This retrospective US claims database analysis using the MarketScan Commercial Claims and Encounters database included patients with mBC receiving olaparib from January 1, 2015 to September 30, 2019. Demographic and clinical characteristics, including hormone receptor (HR) status (HR+ vs non–HR+), were described for the entire study population. Treatment history was described for patients with incident mBC overall and according to HR+ status.

Results

A total of 125 patients with mBC (HR+, n = 64; non–HR+, n = 61) receiving olaparib were identified. Mean age at time of olaparib administration was 52 years (SD, 11.53 years). Patients had a mean (SD) of 2 (1.14) secondary metastatic sites, the majority of which showed bone metastasis (57%). Mean (SD) Charlson Comorbidity Index calculated during the 12-month period before olaparib administration was 7.92 (2.09). A steady increase in olaparib uptake was observed over the study period (16 in 2017; 63 in 2018; 46 up through 9 of 30 in 2019). Among patients with incident mBC (N = 98), 16%, 24%, 26%, and 44% patients received olaparib at first- (1L), second- (2L), third- (3L), and fourth- or greater (4L+) lines, respectively, with the majority (80%) receiving it as monotherapy (HR+ = 78%; non–HR+ = 91%). Most patients with incident HR+ disease (N = 54) received olaparib at a later line (3L = 22%; 4L+ = 63%), whereas most patients with incident non–HR+ disease (N = 44) received olaparib at initial lines (1L = 23%; 2L = 34%). Of the 16 patients with incident mBC on 1L olaparib, 9 received subsequent lines of therapies. Of the patients receiving olaparib as 2L therapy, all patients with HR+ disease (N = 9) received hormonal therapy as monotherapy (N = 5) or in combination with chemotherapy/CDK4/6 inhibitors (N = 4) at 1L, whereas patients with non–HR+ disease (N = 15) mostly received platinum/paclitaxel-based therapy (N = 10) at 1L.

Conclusion

This study provides descriptive information on clinical, demographic, and treatment patterns of olaparib use in real-world settings since its approval. The results show that olaparib was mostly administered as monotherapy and was received mostly at later lines by patients with HR+ disease and earlier lines by patients with non–HR+ disease. Further examination of real-world effectiveness of olaparib in mBC is needed.

Articles in this issue

1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
45 Neoadjuvant Chemotherapy Use in Elderly Patients
45 Neoadjuvant Chemotherapy Use in Elderly Patients